Analysed PHARMALA BIOTECH HOLDINGS IN (MDXXF:OTCMKTS) News Sources
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
06-03-2026
yahoo.com
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order
20-04-2026
yahoo.com
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
27-04-2026
yahoo.com
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
13-05-2026
yahoo.com
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
20-05-2026
yahoo.com
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
20-05-2026
yahoo.com
What is the current price of PHARMALA BIOTECH HOLDINGS IN (MDXXF:OTCMKTS)?
The current price of PHARMALA BIOTECH HOLDINGS IN (MDXXF:OTCMKTS) is $0.1081.
PHARMALA BIOTECH HOLDINGS IN (MDXXF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of PHARMALA BIOTECH HOLDINGS IN (MDXXF:OTCMKTS) since the previous trading day is $0.0094.
PHARMALA BIOTECH HOLDINGS IN (MDXXF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of PHARMALA BIOTECH HOLDINGS IN (MDXXF:OTCMKTS) since the previous trading day is 9.5238%.
What is the most recent average sentiment score for PHARMALA BIOTECH HOLDINGS IN (MDXXF:OTCMKTS)?
The most recent average sentiment score for PHARMALA BIOTECH HOLDINGS IN (MDXXF:OTCMKTS) is 79 out of 100.
What is the most recent average sentiment for PHARMALA BIOTECH HOLDINGS IN (MDXXF:OTCMKTS)?
The most recent sentiment for PHARMALA BIOTECH HOLDINGS IN (MDXXF:OTCMKTS) is .
SEC-8K** Filing Available For PHARMALA BIOTECH HOLDINGS IN (MDXXF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.